C
CRISPR Therapeutics
Transforming Lives with Gene Editing
Boston, MA
1,000+
About CRISPR Therapeutics
Industry:
Gene Editing/Biotechnology
Founded:
2013
Founders:
Emmanuelle Charpentier
Status:
Public (NASDAQ: CRSP)
Funding & Growth
Total Raised:
$2B+
Valuation:
$3B+ market cap
Stage:
Public
Key Investors:
Vertex Pharmaceuticals
Bayer
Public markets
✓ Pros
- • Pioneer in CRISPR gene editing
- • First FDA-approved CRISPR therapy (Casgevy)
- • Partnership with Vertex
- • Cutting-edge science
- • Boston biotech hub location
✗ Cons
- • Volatile biotech stock
- • Competitive job market
- • High pressure to deliver results
- • Regulatory uncertainty